The End of Buy-and-Bill?
This article was originally published in RPM Report
Executive Summary
Doing what was once unthinkable, managed care is eliminating this inveterate approach to physician reimbursement. For pharma, the fallout could be significant. This approach-by which specialty physicians acquire pharmaceuticals from manufacturers and distributors, use them for in-office treatments, and then obtain reimbursements for out-of-pocket expenses from patients' payers-is under siege.